Literature DB >> 12879419

Osteoclast diseases.

Miep H Helfrich1.   

Abstract

Osteoclasts are the only cells capable of resorbing mineralised bone, dentine and cartilage. Osteoclasts act in close concert with bone forming osteoblasts to model the skeleton during embryogenesis and to remodel it during later life. A number of inherited human conditions are known that are primarily caused by a defect in osteoclasts. Most of these are rare monogenic disorders, but others, such as the more common Paget's disease, are complex diseases, where genetic and environmental factors combine to result in the abnormal osteoclast phenotype. Where the genetic defect gives rise to ineffective osteoclasts, such as in osteopetrosis and pycnodysostosis, the result is the presence of too much bone. However, the phenotype in many osteoclast diseases is a combination of osteosclerosis with osteolytic lesions. In such conditions, the primary defect is hyperactivity of osteoclasts, compensated by a secondary increase in osteoblast activity. Rapid progress has been made in recent years in the identification of the causative genes and in the understanding of the biological role of the proteins encoded. This review discusses the known osteoclast diseases with particular emphasis on the genetic causes and the resulting osteoclast phenotype. These human diseases highlight the critical importance of specific proteins or signalling pathways in osteoclasts. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879419     DOI: 10.1002/jemt.10375

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  27 in total

1.  Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation.

Authors:  Jian Zhou; Shiqiao Ye; Toshifumi Fujiwara; Stavros C Manolagas; Haibo Zhao
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

2.  A case of osteopetrosis with acute optic neuropathy.

Authors:  Hirotsugu Tsuchida; Mineo Takagi; Atsushi Miki; Tomoaki Usui; Shigeru Hasegawa; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2008-03-28       Impact factor: 2.447

Review 3.  The osteoclast--what's new?

Authors:  Nicolas A Athanasou
Journal:  Skeletal Radiol       Date:  2011-08-17       Impact factor: 2.199

4.  Phospholipase C-related, but catalytically inactive protein (PRIP) up-regulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling.

Authors:  Ayako Murakami; Miho Matsuda; Yui Harada; Masato Hirata
Journal:  J Biol Chem       Date:  2017-03-24       Impact factor: 5.157

5.  Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence.

Authors:  Wei Chen; Shuying Yang; Yoke Abe; Ming Li; Yucheng Wang; Jianzhong Shao; En Li; Yi-Ping Li
Journal:  Hum Mol Genet       Date:  2007-01-08       Impact factor: 6.150

6.  Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects.

Authors:  Ying Zhang; Manvendra K Singh; Karl R Degenhardt; Min Min Lu; Jean Bennett; Yutaka Yoshida; Jonathan A Epstein
Journal:  Dev Biol       Date:  2008-10-17       Impact factor: 3.582

Review 7.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

8.  Localization and function of the anion exchanger Ae2 in developing teeth and orofacial bone in rodents.

Authors:  Antonius L J J Bronckers; Donacian M Lyaruu; Ineke D C Jansen; Juan F Medina; Sakari Kellokumpu; Kees A Hoeben; Lara R Gawenis; Ronald P J Oude-Elferink; Vincent Everts
Journal:  J Exp Zool B Mol Dev Evol       Date:  2009-06-15       Impact factor: 2.656

9.  Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB.

Authors:  Jeske J Smink; Valérie Bégay; Ton Schoenmaker; Esta Sterneck; Teun J de Vries; Achim Leutz
Journal:  EMBO J       Date:  2009-05-14       Impact factor: 11.598

10.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.